tbuckley/cabot-search huggingface dataset:
OP0077-HPR The effect of an interactive workshop on the adherence with the dutch physical therapy practice guideline for hip and knee osteoarthritis: A randomised controlled trial
Authors: W.F. Peter, P.H. van der Wees, J. Verhoef, Z. de Jong, L. van Bodegom-Vos, W.K. Hilberdink, M. Fiocco, T.P. VlietVlieland
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Literature (1) and daily practice indicate a need for interactive forms of education to enhance guideline usage, but the evidence on their effectiveness is lacking. <h3>Objectives</h3> The aim of this study was to investigate the effectiveness of an interactive workshop as part of the implementation of the Dutch physical therapy (PT) guideline for hip and knee osteoarthritis (HKOA). <h3>Methods</h3> In 5 regions in the Netherlands, all PTs who were a member of the Royal Dutch Society of Physical Therapy were randomly assigned to an interactive workshop (IW) or a control group (C). IW comprised presentations of the content of the guideline and 3 clinical cases with the cooperation of 3 patient partners and 3 expert PTs per region, executed according to the method of clinical reasoning and lasted 3 hours. C was a waiting list group who received IW after 4 months. Assessments were done before the educational course, immediately afterwards and three months thereafter. Assessments consisted of the Quality Indicators for Physical therapy in Hip and Knee Osteoarthritis (QIP-HKOA) questionnaire, containing 18 questions on the usage of the guideline (total score range 0-72), a 19-items knowledge questionnaire (total score range 0-76) and a questionnaire concerning barriers in using the guideline (total score range 0-80). In addition, sociodemographic characteristics of the participants were recorded. Statistical analysis included comparisons of total mean scores between the IW and C across 3 time points by using Linear Mixed Models. <h3>Results</h3> In total 3778 PTs were invited, of whom 275 (7.3%) were willing to take part in the study. They were randomly assigned to IW (n=141) or C (n=134). There were no sociodemografic differences at baseline between IW and C. The statistic analyses showed a significant difference between groups in favour of IW concerning all 3 outcome measures (see Table 1). <h3>Conclusions</h3> An interactive educational course with the support of patients and following a process of clinical reasoning was found to be an effective strategy to improve adherence with recommendations in the Dutch physical therapy guideline for HKOA. Also knowledge about the guideline improved and less barriers to use the guideline were experienced in daily clinical practice after 3 months. <h3>Funding</h3> This project was funded by the Royal Dutch Society of Physical Therapy and the Dutch Arthritis Association. <h3>References</h3> Lineker SC et al. Educational Interventions for Implementation of Arthritis Clinical Practice Guidelines in Primary Care: Effects on Health Professional Behavior, the Journal of Rheumatology 2010; 37:8. <h3>Disclosure of Interest</h3> None Declared
TRANSFEMORAL AORTIC VALVE IMPLANTATION WITH THE NEW EDWARDS SAPIEN 3 VALVE FOR TREATMENT OF SEVERE AORTIC STENOSIS
Authors: Jochen Woehrle, Birgid Gonska, Christoph Rodewald, Julia Seeger, Dominik Scharnbeck, Wolfgang Rottbauer
Journal: Journal of the American College of Cardiology (2016)
Case 5-2004
Authors: Bob S. Carter, James D. Rabinov, Rolf Pfannl, Lee H. Schwamm
Journal: New England Journal of Medicine (2004)

A 57-year-old right-handed man was admitted to the hospital because of the sudden onset of slurred speech and left hemiparesis. Imaging studies revealed an infarct in the area of the right middle cerebral artery. With thrombolysis, recanalization of the vessels was achieved, but the patient's condition continued to worsen.
NI-19 * THE USE OF DYNAMIC O-(2-[18F]fluoroethyl)-L-TYROSINE-PET IN THE CLINICAL EVALUATION OF BRAIN TUMORS IN CHILDREN AND ADOLESCENTS
Authors: V. Dunkl, C. Cleff, G. Stoffels, N. Judov, S. Sarikaya-Seiwert, I. Law, L. Bogeskov, K. Nysom, S. B. Andersen, H.-J. Steiger, G. R. Fink, G. Reifenberger, N. J. Shah, H. H. Coenen, K.-J. Langen, N. Galldiks
Journal: Neuro-Oncology (2014)

BACKGROUND: Experience regarding the use of dynamic O-(2-[18F]-fluoroethyl)-L-tyrosine (18F-FET) PET in children and adolescents with brain tumors is limited. METHODS: Sixty-nine 18F-FET PET scans of 49 patients (median age, 13 years; range, 1-18 years) were analyzed retrospectively. Patients had been referred for: (A) assessment of newly diagnosed cerebral lesions (26 scans in 26 patients), (B) diagnosing tumor progression/recurrence (24 scans in 18 patients), (C) monitoring of chemotherapy effects (8 scans in 4 patients), and (D) the detection of residual tumor tissue after resection (11 scans in 10 patients). Maximum and mean tumor/brain ratios (TBRmax/mean) of 18F-FET uptake were determined (20-40 min p.i.) and time-activity curves were generated and assigned to one of the following patterns: (1) constantly increasing uptake, (2) uptake peaking at a midway point (>20-40 min) followed by a plateau, and (3) uptake peaking early (≤20 min) followed by a constant descent. The diagnostic values of TBRs and kinetic parameters to detect neoplastic tissue or diagnose tumor progression/recurrence were assessed using ROC analyses. Diagnoses were confirmed histologically and/or by clinical course. RESULTS: In patients with newly diagnosed cerebral lesions, highest accuracy (77%) to detect neoplastic tissue (7 of 26 patients) was obtained when TBRmax was >1.7 (AUC, 0.80 ± 0.09; sensitivity, 79%; specificity, 71%, PPV, 88%; P = 0.02). For diagnosing tumor progression/recurrence, highest accuracy (82%) was obtained when curve patterns 2 or 3 were present (AUC, 0.80 ± 0.11; sensitivity, 75%; specificity, 90%, PPV, 90%; P = 0.02). During chemotherapy, a decrease of TBRs was associated with a stable clinical course at least for 6 months. In patients after complete tumor resection (2 of 10 patients), 18F-FET PET detected metabolically active tumor (TBRmax ≥ 1.7). CONCLUSIONS: Our findings suggest that 18F-FET PET can add valuable information for clinical decision-making in pediatric brain tumor patients.
Abstract 4012: GANT-61 inhibits pancreatic cancer stem cell growth i<i>n vitro</i> and in NOD/SCID/IL2R gamma null mice xenograft.
Authors: Junsheng Fu, Mariana Rodova, Sanjit K. Roy, Sharmila Shankar, Rakesh K. Srivastava
Journal: Cancer Research (2013)

Abstract Multiple lines of evidence suggest that the Sonic Hedgehog (Shh) signaling pathway is aberrantly reactivated in pancreatic cancer stem cells (CSCs). The objectives of this study were to examine the molecular mechanisms by which GANT-61 (Gli transcription factor inhibitor) regulates stem cell characteristics and tumor growth. Effects of GANT-61 on CSC's viability, spheroid formation, apoptosis, DNA-binding and transcriptional activities, and epithelial-mesenchymal transition (EMT) were measured. Humanized NOD/SCID/IL2Rgammanull mice were used to examine the effects of GANT-61 on CSC's tumor growth. GANT-61 inhibited cell viability, spheroid formation, and Gli-DNA binding and transcriptional activities, and induced apoptosis by activation of caspase-3 and cleavage of Poly-ADP ribose Polymerase (PARP). GANT-61 increased the expression of TRAIL-R1/DR4, TRAIL-R2/DR5 and Fas, and decreased expression of PDGFRα and Bcl-2. GANT-61 also suppressed EMT by up-regulating E-cadherin and inhibiting N-cadherin and transcription factors Snail, Slug and Zeb1. In addition, GANT-61 inhibited pluripotency maintaining factors Nanog, Oct4, Sox-2 and cMyc. Suppression of both Gli1 plus Gli2 by shRNA mimicked the changes in cell viability, spheroid formation, apoptosis and gene expression observed in GANT-61-treated pancreatic CSCs. Furthermore, GANT-61 inhibited CSC tumor growth which was associated with up-regulation of DR4 and DR5 expression, and suppression of Gli1, Gli2, Bcl-2, CCND2 and Zeb1 expression in tumor tissues derived from NOD/SCID IL2Rγ null mice. Our data highlight the importance of Shh pathway for self-renewal and metastasis of pancreatic CSCs, and also suggest Gli as a therapeutic target for pancreatic cancer in eliminating CSCs. Citation Format: Junsheng Fu, Mariana Rodova, Sanjit K. Roy, Sharmila Shankar, Rakesh K. Srivastava. GANT-61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/IL2R gamma null mice xenograft. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4012. doi:10.1158/1538-7445.AM2013-4012
COMPARISON OF NEOATHEROSCLEROSIS PATTERN BETWEEN PATIENTS WITH AND WITHOUT DIABETES: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Lei Gao, Tomonori Itoh, So-Yeon Choi, Seung-Jung Park, Yangsoo Jang, Stephen Lee, Jinwei Tian, Yoshiyasu Minami, Haibo Jia, Daniel Ong, Tsunenari Soeda, Rocco Vergallo, Hang Lee, Bo Yu, Shiro Uemura, Ik-Kyung Jang
Journal: Journal of the American College of Cardiology (2015)
Abstract 4769: Growth hormone-releasing hormone (GHRH) antagonist attenuates cell motility of human endometrial cancer by down-regulating Twist and N-Cadherin expression.
Authors: Hsien-Ming Wu, Andrew V. Schally, Peter C.K. Leung
Journal: Cancer Research (2013)

Abstract Introduction : More than 25% of patients diagnosed with endometrial carcinoma have an invasive primary cancer accompanied by metastases. GHRH is secreted by the hypothalamus and stimulates the synthesis and secretion of GH from the pituitary. The expression of GHRH and its receptors has been demonstrated in peripheral tissues. In recent years, many antagonistic analogs of GHRH were developed. GHRH antagonists have effects on tumor cells, but the underlying molecular mechanism is not well known. Although Twist and N-Cadherin play important roles in cancer cell motility, it is not established whether Twist and N-Cadherin are required for GHRH antagonists-attenuated cell motility on endometrial cancer cells. In the present study, we examined the action of GHRH antagonist-attenuated cell motility and the mechanisms of the action in endometrial cancer. Methods and Materials : Endometrial cancer cell line Ishikawa and ECC-1 were derived from an endometrial adenocarcinoma. GHRH antagonist MIA-602 was synthesized by solid phase methods. Cell motility was estimated by invasion and migration assay. Immunoblot analysis and RT-PCR were performed to investigate the expression of GHRH receptor, GHRH, and the effects of GHRH antagonist in Twist and N-Cadherin. Human GHRH receptor siRNA was used to knock down the expression of GHRH receptor for elucidating the mechanisms of GHRH antagonist action. Results : The GHRH receptor was expressed in human endometrial cancer cells. The GHRH antagonist attenuated cell motility in a dose-dependent manner. GHRH antagonist-attenuated cell motility was restored in cells pretreated with GHRH receptor siRNA. GHRH antagonist suppressed Twist and N-Cadherin signaling. Knockdown of GHRH receptor with siRNA recovered the expression of Twist and N-Cadherin signaling. Conclusions These results demonstrate that the GHRH antagonist suppressed the cell motility of human endometrial cancer through the GHRH receptor and the down-regulation of Twist and N-Cadherin. Our findings represent a new concept regarding the mechanisms of GHRH antagonist-suppressed cell motility in human endometrial cancer, suggesting the possibility of GHRH antagonist as a potential therapeutic intervention for the treatment of human endometrial cancer. Citation Format: Hsien-Ming Wu, Andrew V. Schally, Peter C.K. Leung. Growth hormone-releasing hormone (GHRH) antagonist attenuates cell motility of human endometrial cancer by down-regulating Twist and N-Cadherin expression. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4769. doi:10.1158/1538-7445.AM2013-4769 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
AB0600 Alfacalcidol (D-hormone analog) modulate inflammatory cytokine production without conversion to calcitriol
Authors: J. Vojinovic, T. Zivanovic-Radnic, M. Sefik-Bukilica, K. Simic-Pasalic, N. Damjanov
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> D hormone 1,25(OH)2D3 (calcitriol) is believed to be the only active form of D hormone (synthesized from vitamin D - cholecalciferol) within the body. It is well known that high doses of D hormone exert immunomodulatory properties that could benefit rheumatoid arthritis [1]. Alfacalcidol, synthetic D hormone analogue 1(OH)D3, compared to calcitriol, is known for its safer profile (lower hypercalcemic activity) when used in higher doses. Mostly it is used for prophylaxis and treatment of osteoporosis, but some encouraging results were achieved in rheumatoid arthritis as well [2]. Actually it is believed that alfacalcidol must be hydroxylated at 25 position (conversion to calcitriol) to induce any effect on cells. <h3>Objectives</h3> Aim of the study was to investigate if alfacalcidol itself could influence cytokine production, as calcitriol does, shifting Th1 to Th2 profile. <h3>Methods</h3> Isolated peripheral blood mononuclear cells (PBMC), from 20 healthy volunteers, were stimulated with PMA and Ionomycin and cultivated in cell cultures (48 hours at 37°C, 5% CO<sub>2</sub>) medium without supplements or supplemented with 10 nM of alfacalcidol or calcitriol, respectively. Produced levels of IL-17A, IL-21, IL-23, IFN-γ, TNF-α, and IL-4 were measured in cell culture supernatant by standard manufacturer ELISA method. <h3>Results</h3> In vitro test results have shown that alfacalcidol can act on cells directly, and there was no statistically significant difference compared to calcitriol. Compared to controls, without any supplements in culture, alfacalcidol and calcitriol significantly reduced production of IL-17 (p&lt;0.001), IL-21 (p&lt;0.001) and TNF-α (p&lt;0.05) while increased production of IL-4 (p&lt;0.001) and IFN-γ (p&lt;0.05). Production of IL-23 was not influenced by both types of D- hormone. <h3>Conclusions</h3> This is the first prove that alfacalcidol, as a synthetic vitamin D analogue, may act on cells directly, without 25-hydroxylation to calcitriol. Same as calcitriol, it has immunomodulatory potential, promoting Th2 while inhibiting Th1-cytokine profile. Better safety profile when used in high doses and ability to suppress Th17 production in activated cells could provide considerable therapeutic potential on lymphocyte differentiation and osteoclasts benefiting RA and secondary osteoporosis. <h3>References</h3> Cutolo M. Vitamin D and autoimmune rheumatic diseases. Arthritis Research &amp; Therapy 2008; 10:123-4 Andjelkovic Z, Vojinovic J, Pejnovic N et al. Disease modifynig and immunoregulatory effects of high oral dose 1a(OH)D3 in rheumatoid arthritis patients. Clin Exp Rheumatol 1999; 17(4): 59-62. <h3>Disclosure of Interest</h3> None Declared
DIGOXIN USE AT DISCHARGE IS ASSOCIATED WITH REDUCED INTERSTAGE MORTALITY AFTER STAGE I PALLIATION FOR SINGLE VENTRICLE HEART DISEASE
Authors: David W. Brown, Colleen Mangeot, Jeffrey Anderson, Laura E. Peterson, Eileen King, Stacey Lihn, Steven Neish, Robert Beekman, Carole Lannon
Journal: Journal of the American College of Cardiology (2015)
Abstract 1324: PMEPA1 enhances the prostate cancer cell growth inhibitory effect of MDV3100 and bicalutamide.
Authors: Hua E. Li, Daniel Heidenberg, Albert Dobi, Shiv Srivastava
Journal: Cancer Research (2013)

Abstract Introduction and Objective: PMEPA1 is a highly androgen-inducible gene in prostate cancer cells, recruits the NEDD4-1, an E3 ubiquitin ligase, to degrade AR. We hypothesize that the frequently (65%) observed decrease or loss of PMPEA1 expression in human prostate tumors may lead to enhanced AR functions and accelerated prostate tumorigenesis. Therefore, we investigated the growth and survival of prostate cancer cells in the presence of AR inhibitors in response to PMEPA1 knockdown. Methods: PMEPA1 was silenced by PMEPA1 Mission shRNA lentivirus infection and puromycin selection in LNCaP and VCaP cells respectively. The PMEPA1 deficient LNCaP and VCaP cells were treated with the AR inhibitors (MDV3100 and bicalutamide), as well as the artificial synthesized androgen R1881. Ectopic NEDD4-1 was expressed by pCMV-XL4-NEDD4-1 eukaryotic expression vector. Cell growth was monitored by cell counting assay, BrdU incorporation assay and colony plating efficiency assay. Cell cycle was analyzed with propidium iodide staining based flowcytometry assay. Protein levels of AR, PMEPA1, PSA and NEDD4-1 were assessed by immunoblot assays. Results: PMEPA1 silenced LNCaP and VCaP cells had higher AR, PSA protein levels, suggesting activated AR signaling. Consistent with this observation, inhibition of PMEPA1-1 by shRNA resulted in increased cell growth, stronger BrdU incorporation ability and higher colony plating efficiency in both LNCaP and VCaP cells. Cell cycle assay showed more S-phase cells in PMEPA1 deficient LNCaP and VCaP cells in regular medium or R1881 supplemented charcoal-striped medium. Ectopic expression of NEDD4-1 could not inhibit cell growth in PMEPA1 silenced LNCaP cells. More interestingly, the PMEPA1 deficient CaP cells (both LNCaP and VCaP cells) demonstrated more resistance to the growth inhibitory effects of MDV3100 and bicalutamide. Conclusions: The frequently observed decreased expression of PMEPA1 results in elevated AR protein levels and activated AR signaling, which in turn promotes cell growth in androgen responsive prostate cancer cells. The PMEPA1 deficient cells develop more resistance to AR inhibitors. Our findings further suggest the important role of decreased PMEPA1 in AR related prostate tumorigenesis. These data highlight that PMEPA1 deficiency may confer resistance to AR inhibitors during CaP progression. This study is supported by the NIH grant (R01CA106653) to SS. Citation Format: Hua E. Li, Daniel Heidenberg, Albert Dobi, Shiv Srivastava. PMEPA1 enhances the prostate cancer cell growth inhibitory effect of MDV3100 and bicalutamide. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1324. doi:10.1158/1538-7445.AM2013-1324
P716Assessment of right ventricular myocardial systolic activation in children with pulmonary hypertension using tissue doppler imaging
Authors: W Gomaa Ibrahim
Journal: Cardiovascular Research (2014)

Background: Tissue Doppler imaging (TDI) has provided an objective means to quantify global and regional ventricular functions with improved accuracy and greater reproducibility than conventional echocardiography. This study was conducted to assess right ventricular (RV) myocardial systolic activation by TDI in children with pulmonary arterial hypertension (PAH). Methods: Forty pediatric patients with PAH and 20 healthy controls, underwent standard echocardiogram and TDI. In the apical 4 chamber view the following regional parameters were evaluated in three different myocardial segments (RV basal lateral, basal septal and LV basal lateral): systolic (Sm), early- and late-diastolic (Em and Am) peak velocities. RV myocardial systolic activation delay was defined as the difference in time to peak TDI systolic velocities between the RV basal lateral wall and basal septal. In addition, RV end-diastolic and end-systolic areas were measured to calculate RV fractional area change (FAC). Results: Compared with the control group, pediatric patients with PAH showed reduced RV FAC; 37.6±14% versus 48±5% (P0.0024). The patients group showed lower myocardial peak velocities and a significant activation delay compared with controls (P0.0001). There was a significant negative correlation between RV myocardial systolic activation delay and RV FAC. RV myocardial systolic activation delay was even present in a subset of patients with normal FAC. Conclusions: In PAH, RV myocardial systolic activation was markedly delayed and showed significant negative correlation with the RV FAC. RV myocardial systolic activation delay could offer a unique approach to predict early RV dysfunction before the decline in RV FAC is evident.
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
Authors: William P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge, Katherine Y. Look, Daniel L. Clarke-Pearson, Martin Davidson
Journal: New England Journal of Medicine (1996)

Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide long-term control of disease in few patients, however. We compared two combinations, cisplatin and cyclophosphamide and cisplatin and paclitaxel, in women with ovarian cancer.We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin (75 mg per square meter of body-surface area) with either cyclophosphamide (750 mg per square meter) or paclitaxel (135 mg per square meter over 24 hours).Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-paclitaxel group. Among 216 women with measurable disease, 73 percent in the cisplatin-paclitaxel group responded to therapy, as compared with 60 percent in the cisplatin-cyclophosphamide group (P = 0.01). The frequency of surgically verified complete response was similar in the two groups. Progression-free survival was significantly longer (P < 0.001) in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group (median, 18 vs. 13 months). Survival was also significantly longer (P < 0.001) in the cisplatin-paclitaxel group (median, 38 vs. 24 months).Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer.
A cost-effective and minimally-invasive approach to mediastinal lymphadenopathy
Authors: KL Khoo, KY Ho, C Khor, B Nilsson, TK Lim
Journal: Endoscopy (2006)

Introduction: To determine the optimal approach to cytopathologic evaluation of mediastinal lymphadenopathy utilizing transbronchial needle aspiration (TBNA) and endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA).
LEFT VENTRICULAR DYSFUNCTION HAS AN ADDITIONAL NEGATIVE IMPACT ON CARDIAC OUTCOMES IN ADULTS WITH EBSTEIN'S ANOMALY
Authors: Yumi Shiina, Sonya Babu-Narayan, Koichiro Niwa, Riikka Rydman, Wei Li, Theodor Karonis, Vasilis Papaioannou, Oktay Tutarel, Aleksander Kempny, Gerhard-Paul Diller, Philip Kilner, Hideki Uemura, Michael Gatzoulis
Journal: Journal of the American College of Cardiology (2014)
Successful closure of an endoscopic ultrasound-induced duodenal perforation using an over-the-scope-clip
Authors: Benedetto Mangiavillano, Monica Arena, Elisabetta Morandi, Tara Santoro, Enzo Masci
Journal: Endoscopy (2014)

Perforation of the duodenum is one of the most feared adverse events during upper gastrointestinal tract operative endoscopy and, in particular, during endoscopic ultrasonography (EUS). A recent study by Carrara et al. reported a duodenal perforation rate of 0.09 % in a series of 3296 patients who underwent EUS-guided fine-needle aspiration [1].